America’s biopharmaceutical research companies are developing 435 innovative new medicines to target 15 leading chronic conditions affecting the Medicare population, according to a new report released by the Pharmaceutical Research and Manufacturers of America last week.
Novo Nordisk on Thursday announced the launch of Levemir FlexTouch (insulin detemir [rDNA origin] injection), a prefilled insulin delivery mechanism, providing a new way for diabetics to administer their insulin.
Canada’s Federal Court ruled recently that the country’s Patented Medicine Prices Review Board — a federal tribunal that regulates pricing on branded medicines — could not extend price-control measures to cover generic drug companies, according to published reports.
Valeant Pharmaceuticals International announced that its subsidiary, Valeant Pharmaceuticals North America, received approval from the Food and Drug Administration for its new drug application for Jublia (efinaconazole 10% topical solution). The drug is the first topical triazole approved for the treatment of onychomycosis of the toenails, the company said.
Auxilium Pharmaceuticals, a specialty biopharmaceutical company, on Wednesday announced that it has partnered with Prasco to debut the authorized generic form of Testim gel, which is used to treat adult males with low or no testosterone.